pargyline has been researched along with Attention Deficit Disorder with Hyperactivity in 2 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Attention Deficit Disorder with Hyperactivity: A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wender, PH | 2 |
| Wood, DR | 2 |
| Reimherr, FW | 2 |
| Ward, M | 1 |
1 trial available for pargyline and Attention Deficit Disorder with Hyperactivity
| Article | Year |
|---|---|
An open trial of pargyline in the treatment of attention deficit disorder, residual type.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Female; Humans; Male | 1983 |
1 other study available for pargyline and Attention Deficit Disorder with Hyperactivity
| Article | Year |
|---|---|
Pharmacological treatment of attention deficit disorder, residual type (ADD,RT, "minimal brain dysfunction," "hyperactivity") in adults.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Humans; Methylphenidate; Pargyline; Pemoline; | 1985 |